Edwards Lifesciences Corporation

EW · NYSE · ·

Karşılaştır

$105,85%0,012 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 4 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%3,6
1M: +%24,1

Edwards Lifesciences Corporation (EW) hisse senedi — iyi bir şirket mi? — InspectStocks

Edwards Lifesciences Corporation

EW · NYSE · ·

Karşılaştır

$105,85%0,012 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 4 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: +%3,6
1M: +%24,1

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of 4 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$1,72B
+%10 y/y
-%1,5 q/q
Guided
$1,67B
midpoint
Above guide+%2,7
EPS, GAAP
Actual
$0,53
+%6,0 y/y
+%26 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$299,1M
-%2,6 y/y
-%42 q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue$1,67B – $1,75B+%8,9 y/y First given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Nasıl para kazanıyor

Catheter-delivered aortic valve replacement%72
Catheter-delivered mitral and tricuspid valve repair and replacement%11
Surgical heart valve products%16

Gelir payları nine months ended September 30, 2026 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

2 tane daha göster

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Kim alıyor3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

Ters gidebilecekler

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Tüm finansal tablolar →

Edwards Lifesciences Corporation hakkında

Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.

Merkez: Irvine, California, United States
Kuruluş: 1958
Çalışan sayısı: Approximately 16,000 (December 31, 2025, medium)
İşlem gördüğü borsa: New York Stock Exchange
Mali yıl sonu: December 31

Edwards Lifesciences Corporation şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Just reported

Q3 2026 results

From Edwards Lifesciences's results release of 4 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$1,72B
+%10 y/y
-%1,5 q/q
Guided
$1,67B
midpoint
Above guide+%2,7
EPS, GAAP
Actual
$0,53
+%6,0 y/y
+%26 q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$299,1M
-%2,6 y/y
-%42 q/q
Guided
—
No guide given

Company outlook

Q4 2026

Revenue$1,67B – $1,75B+%8,9 y/y First given

Keep exploring

The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Medical Devices

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Nasıl para kazanıyor

Catheter-delivered aortic valve replacement%72
Catheter-delivered mitral and tricuspid valve repair and replacement%11
Surgical heart valve products%16

Gelir payları nine months ended September 30, 2026 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor5

SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.

2 tane daha göster

SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.

Kim alıyor3

Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.

Ters gidebilecekler

1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.

Tüm finansal tablolar →

Edwards Lifesciences Corporation hakkında

Merkez: Irvine, California, United States
Kuruluş: 1958
Çalışan sayısı: Approximately 16,000 (December 31, 2025, medium)
İşlem gördüğü borsa: New York Stock Exchange
Mali yıl sonu: December 31

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor5

Kim alıyor3

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Edwards Lifesciences Corporation hakkında

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor5

Kim alıyor3

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Edwards Lifesciences Corporation hakkında

Keep exploring

The theme it is part of

Highest-graded in Medical Devices

Grade rose recently in Healthcare

Medical devices

Büyüme ve nakit — 5 üzerinden 5

İş eğilimi

Zaman içinde hisse fiyatı ve not